drugset / Trial / NCT03656692

Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)

NCT03656692

Phase 4 Terminated 5 enrolled Mallinckrodt
NaSingle-groupOpen-labelTreatment

Summary

The main reason for this study is to see if Acthar Gel can reduce inflammation in the uvea. Also, safety information when using it for this purpose will be collected.

Timeline

Start
2018-10-05
Primary completion
2020-07-14
Completion
2020-07-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Acthar Peptide 80 iu Subcutaneous